{
    "2020-11-20": [
        [
            {
                "time": "2021-11-09",
                "original_text": "Canada grants interim authorization to Eli Lilly's COVID-19 antibody drug",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "COVID-19",
                        "antibody drug",
                        "interim authorization"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "U.S. sees spike in daily COVID-19 cases, hospitalizations surge",
                "features": {
                    "keywords": [
                        "U.S.",
                        "spike",
                        "COVID-19 cases",
                        "hospitalizations"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19",
                "features": {
                    "keywords": [
                        "Lilly",
                        "neutralizing antibody",
                        "bamlanivimab",
                        "interim authorization",
                        "Health Canada",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Eli Lilly: Back From the Depths",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Back From the Depths"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19",
                "features": {
                    "keywords": [
                        "Lilly/Incyte",
                        "Olumiant",
                        "FDA",
                        "Emergency Nod",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More",
                "features": {
                    "keywords": [
                        "Pharma Stock",
                        "PFE",
                        "COVID-19 Vaccine",
                        "Final Analysis",
                        "FDA Updates"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Eli Lilly Gets FDA Approval For COVID Treatment, WHO Doubts Gilead's Remdesivir",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "FDA Approval",
                        "COVID Treatment",
                        "WHO",
                        "Gilead",
                        "Remdesivir"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Lilly's arthritis drug and Gilead's Veklury receive FDA authorization as combination COVID-19 treatment",
                "features": {
                    "keywords": [
                        "Lilly",
                        "arthritis drug",
                        "Gilead",
                        "Veklury",
                        "FDA authorization",
                        "combination",
                        "COVID-19 treatment"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger",
                "features": {
                    "keywords": [
                        "Daily Biotech Pulse",
                        "Amarin",
                        "Vascepa Data",
                        "Mesoblast",
                        "Novartis Deal",
                        "Decision Day",
                        "Eiger"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Precision BioSciences",
                        "Genome Editing",
                        "Research Collaboration",
                        "License Agreement"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Eli Lillyâ€™s Baricitinib Gets FDA Approval for Emergency Use with Remdesivir to Treat COVID-19 Patients",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Baricitinib",
                        "FDA Approval",
                        "Emergency Use",
                        "Remdesivir",
                        "COVID-19 Patients"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-09",
                "original_text": "Eli Lilly's Arthritis Drug Gets Emergency Use Approval For Treatment Of COVID-19",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Arthritis Drug",
                        "Emergency Use Approval",
                        "Treatment",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}